Given STAT3 is a target of IL-6 and the well described association of poorer outcomes in patients with solid tumors and higher levels of systemic inflammatory scores [21], ruxolitinib has been evaluated in several solid tumor types outside of breast cancer which have all not demonstrated a significant improvement in clinical outcomes [22–25]. This evidence concerns the gene STAT3 and breast carcinoma.